Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

NSE: ZYDUSLIFE BSE: 532321

₹1188.10

-52.50 (4.23%)

Sat, 07 Nov 2026, 10:51 pm

mtf coin illustrationMTF 5xInvest in Zydus Lifesciences Ltd with 5x LeverageBuy with MTFpremium button ring illustration
Market Cap (in Cr)123590.72
PE Ratio26.48
Dividend0.08
Health TechnologyHealth Technology
Pharmaceuticals: MajorPharmaceuticals: Major
24.5K24.5K

Zydus Lifesciences Share Price Live Chart

1 Day

-52.50 (4.23%)

No Result Found

Summary

  • Market Cap (in Cr)

    119201.71

  • Net Profit (in Cr)

    5026.4

  • P/B

    3.23

  • Sector P/E

    39.36

  • P/E

    17.39

  • EV/EBITDA

    11.66

  • Debt/Equity (Industry)

    0.19

  • Interest Cover (Industry)

    13.14

  • ROCE (Industry)

    12.29

  • RONW (Industry)

    10.69

  • ROE

    19.69

  • ROCE

    20.30

  • Debt/Equity

    0.31

  • EPS (TTM)

    45.56

  • Dividend Yield

    0.08

  • Book Value

    278.87

  • Interest Cover

    16.09

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersSEPT 2026JUN 2026MAR 2026DEC 2025SEPT 2025
Promoters75.0175.0175.0075.0074.99
FII7.056.886.957.067.34
DII11.2811.2711.2011.0910.86
Public6.666.836.856.856.80
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

56.37

MACD

17.50

50 DMA

1157.52

200 DMA

1040.64

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1506.771351.371298.431195.971143.031040.57885.17
Fibonacci1351.371292.001255.331195.971136.601099.931040.57
Camarilla1288.241273.991259.751195.971231.251217.011202.76

Pivots Level: Classic

R3

+310.80

1506.77

R2

+155.40

1351.37

R1

+102.47

1298.43

1195.97
1195.97
Pivot Point
LTP: 1197.90

S1

-52.93

1143.03

S2

-155.40

1040.57

S3

-310.80

885.17

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1194.00

  • 20-EMA

    1178.36

  • 30-EMA

    1169.62

  • 50-EMA

    1157.81

  • 100-EMA

    1127.19

  • 200-EMA

    1076.30

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
04 Nov 2026board-meetingsQuarterly Results
19 May 2026dividend₹1.00 Dividend /Share24 Jul 2026
19 May 2026buyback
19 May 2026agm
19 May 2026board-meetingsQuarterly Results, Final Dividend
09 Feb 2026board-meetingsQuarterly Results
06 Nov 2025board-meetingsQuarterly Results
25 Jun 2025dividendFinal Dividend - Rs. - 1125 Jul 2025
20 May 2025agm
19 May 2025dividend₹11.00 Dividend /Share25 Jul 2025

Read More

Peer Comparison

Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

Laurus Labs Ltd logo

Laurus Labs Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Read More

Zydus Lifesciences Ltd About

Zydus Lifesciences operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.(Source : 202503-Annual Report Page No:291)

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1995

Headquarters

CEO

Pankaj R Patel

Employees

Contact

Website icon

Website

http://www.zyduscadila.com

Email icon

Email

dhavalsoni@zyduscadila.com; upen.shah@zyduscadila.

Phone icon

Phone

91-079-26868100

Location icon

Location

Zydus Corporate Park S No 536, Khoraj Sarkhej-Gandhinagar H/W, Ahmedabad, Gujarat, 382481

Read More

Zydus Lifesciences Ltd Company History

YearHistory
2020
  • Zydus and CMS entered pact for Desidustat in Greater China.
  • Zydus Wellness launched hand sanitizer under Nycil brand.
  • Zydus Cadila launched COVID-19 drug Remdesivir in India.
  • Zydus Cadila launched new product for COPD patients in India.
2021
  • Zydus Cadila launched Trastuzumab Emtansine under brand Ujvira.
  • Cadila Healthcare received orphan drug designation for malaria treatment compound.
2022
  • Zydus Life received USFDA final approvals for Silodosin and Pregabalin.
  • Zydus Group had 338 approvals and filed over 431 ANDAs.
  • Zydus Life received final USFDA approval for Topiramate extended-release capsules.
  • Zydus Lifesciences' arm received EC approval for MoCD injection.
  • Received Pharma Company of the Year Award, Excellence in CSR, and 7th India Pharma CSR award.
2023
  • Zydus Lifesciences inked licensing pact with Daewoong Pharmaceutical.
  • Zydus Lifesciences received USFDA approval for Acyclovir Cream.
  • Sentynl Therapeutics completed asset transfer of CUTX-101 from Cyprium Therapeutics.
  • Zydus Lifesciences received 7th CSR Health Impact Award.
2024
  • Zydus Lifesciences received WHO prequalification for Typhoid Vi conjugate vaccine.
  • Zydus Lifesciences received Mexican regulatory approval for cancer treatment biosimilar.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
UBS PRINCIPAL CAPITAL ASIA LIMITEDbulkSell67016641128.1130 Aug 2024
INTEGRATED CORE STRATEGIES (ASIA) PTE.LTD.bulkBuy5460159258.2128 May 2019
BLACKROCK FUNDS INTERNATIONAL OPPORTUNITIES PORTFbulkBuy710279740330 Nov 2015
BLACKROCK FUNDS INTERNATIONAL OPPORTUNITIES PORTFbulkSell555000402.7930 Nov 2015
BARING INDIA PRIVATE EQUITY FUND III LISTED INVESTMENTS LTDblockSell4604326427.7527 Oct 2015
BARCLAYS MERCHANT BANK (SINGAPORE) LTDblockBuy4604326427.7527 Oct 2015
BARING INDIA PRIVATE EQUITY FUND III LISTED INVESTMENTS LTDblockSell2169720435.520 Oct 2015
BARCLAYS MERCHANT BANK (SINGAPORE) LTDblockBuy2169720435.520 Oct 2015
BARCLAYS MERCHANT BANK (SINGAPORE) LTDblockBuy155983942414 Oct 2015
BARING INDIA PRIVATE EQUITY FUND III LISTED INVESTMENTS LTDblockSell155983942414 Oct 2015

Read More

Zydus Lifesciences Ltd News

Zydus Saroglitazar shows promise in MASH trial

Zydus Therapeutics reported Phase 2b data showing 39.1% steatohepatitis resolution with 4mg saroglitazar vs 13.7% placebo in MASH patients with fibrosis.

06 Nov 2026

companies

LIC cuts Zydus Lifesciences stake to 3.184%

Life Insurance Corporation of India reduced its holding in Zydus Lifesciences Ltd to 3.184% after selling 20,242,068 shares in the open market between August 2025 and November 2026.

06 Nov 2026

companies

Zydus to join Avendus Spark conference

Zydus Lifesciences will participate in the Avendus Spark Investor Conference in Mumbai on November 17, 2026. The company filed this disclosure with BSE and NSE.

05 Nov 2026

companies

Zydus Lifesciences to attend JM Financial conference

Zydus Lifesciences will participate in the JM Financial 17th Annual Flagship Conference in Mumbai on November 18, 2026.

05 Nov 2026

companies

Zydus appoints Walker Chandiok as auditor

Zydus Lifesciences Ltd has appointed Walker Chandiok & Co LLP as statutory auditors for a 5-year term starting FY27, replacing Deloitte under mandatory rotation rules.

04 Nov 2026

companies

Read More

Frequently Asked Questions

  • 1.What is the stock price of Zydus Lifesciences Ltd?

    As of 08/11/2026 at 4:21 AM, Zydus Lifesciences Ltd shares are trading at ₹1188.10.

  • 2.What is the market cap. of Zydus Lifesciences Ltd?

    As of 08/11/2026, the market capitalization of Zydus Lifesciences Ltd is ₹1,23,590.72 crore.

  • 3.When was Zydus Lifesciences Ltd founded?

    Zydus Lifesciences Ltd was founded in 1995.

  • 4.What are the P/E and P/B ratios of Zydus Lifesciences Ltd?

    As of 08/11/2026, Zydus Lifesciences Ltd has a P/E ratio of 26.48 and a P/B ratio of 3.23.

  • 5.How can I buy shares of Zydus Lifesciences Ltd?

    You can buy shares of Zydus Lifesciences Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.

  • 6.What is the shareholding pattern of Zydus Lifesciences Ltd?

    As of September,2026, promoters hold 75.01% in Zydus Lifesciences Ltd, while FIIs, DIIs and public shareholders hold 7.05%, 11.28% and 6.66%, respectively. The government holds 0.00%.

  • 7.Does Zydus Lifesciences Ltd pay dividends?

    Yes, Zydus Lifesciences Ltd pays dividends to eligible shareholders. The latest dividend announced by the company was ₹₹1.00 Dividend /Share per share.

  • 8.What is the dividend yield of Zydus Lifesciences Ltd?

    As of 08 November, 2026, the dividend yield of Zydus Lifesciences Ltd stands at 0.08%.

  • 9.What are the latest financial results of Zydus Lifesciences Ltd?

    For the financial year ended March 2025, Zydus Lifesciences Ltd reported revenue of ₹22,857.00 crore and a net profit of ₹4,526.00 crore.

  • 10.What is the Stock symbol of Zydus Lifesciences Ltd?

    ZYDUSLIFE is the stock symbol of Zydus Lifesciences Ltd.

  • 11.Who is the CEO of Zydus Lifesciences Ltd?

    The CEO of Zydus Lifesciences Ltd is Pankaj R Patel.

pocketful logo lightpocketful logo dark
PricingBecome a Partner
search icon
/

No results for ''

Popular search

  • popular search iconSuzlon Energy Ltd
  • popular search iconIndian Railway Finance Corporation Ltd
  • popular search iconTata Motors Ltd
  • popular search iconTata Steel Ltd
  • popular search iconRail Vikas Nigam Ltd

Recent search

      Log In
      search icon

      No results for ‘’

        Popular search

        • popular search iconSuzlon Energy Ltd
        • popular search iconIndian Railway Finance Corporation Ltd
        • popular search iconTata Motors Ltd
        • popular search iconTata Steel Ltd
        • popular search iconRail Vikas Nigam Ltd
        • popular search iconReliance Industries Ltd
        pocketful logo lightpocketful logo dark
        • Pricing
        • Become a Partner
        Log In
        • home icon
        • arrow iconstocks
        • arrow iconzydus lifesciences ltd
        • Overview
        • Financials
        • Ratios
        • shareholding
        • Technical Analysis
        • Corporate Actions
        • Peer Comparison
        • About
        • Company History
        • Deals
        • News
        • FAQs

        Open Your Free Demat Account Now!

        Step into a world of zero fees and limitless opportunities!

        pocketful logo
        • Quick Links

          • Open Demat Account
          • Pocketful Web
          • Pocketful App
          • Pricing
          • Authorised Person
          • Pocketful Calculators
          • Compliance Links
        • Pages

          • Tools
          • Blogs
          • ETF Screener
          • IPO
          • ETF
          • Bonds
          • Index Heat Map
        • Products

          • Stocks
          • Commodity
          • Subscription
          • Free Stock Screener
          • Pocketful GPT
          • MTF
          • Mutual Funds
        • Company

          • About us
          • Contact us
          • Terms and Conditions
          • Policies & Procedures
          • Privacy Policy
          • Disclosure
          • Careers
        • Socials

          • Facebook iconFacebook
          • Twitter iconTwitter
          • Instagram iconInstagram
          • LinkedIn iconLinkedIn
          • Youtube iconYoutube

        2022-25 Pocketful. All rights reserved, Built with in India

        Version -5.76

        app image 1app image 2

        Stocks:

        AllABCDEFGHIJKLMNOPQRSTUVWXYZ

        Explore

        Calculators
        Popular Calculators
        Group Stocks
        Asset Management Companies
        Popular Stocks
        Indian Indices
        Sector Wise Stocks
        IPO
        Share Market
        Best MF Schemes
        Platforms
        Resources
        Gold Rates in Top Cities
        Silver Rates in Top Cities

        Others:

        NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

        Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800